Abstract
When asked to write this editorial, I initially demurred, reasoning that the subject at hand is the subject of 2 randomized controlled studies of almost 1500 subjects; and both have reported their initial results. The European Organization for Research and Treatment of Cancer trial, a study of about 1000 men, has reported their short-term results: a significant reduction in prostate-specific antigen relapse with radiotherapy.1 The Southwestern Oncology Group 8794 trial, with longer follow-up, showed an even greater reduction in biochemical failure, delaying the median time to failure by 7 years.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
